Showri Karnam
Interventional Cardiology · Parkersburg, WVNPI 1447458401
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,162 of the $9,786 with a category attached, or 63.0%. 34 manufacturers reported payments, led by Medtronic at 37.5% of the total.
Across 346 payments — averaging $28.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$984
- Penumbra, Inc.$969
- Novartis$649
- Boston Scientific$630
- E.r. Squibb & Sons, L.L.C.$535
- plus $2K from 28 others
What the payments were for
- Travel & lodging$3,24233%
- Food & beverage$6,16263%
- Education$3824%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 38 | $3,674 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 66 | $984 |
| Penumbra, Inc. | 7 | $969 |
| Novartis | 47 | $649 |
| Boston Scientific | 24 | $630 |
| E.r. Squibb & Sons, L.L.C. | 34 | $535 |
| AstraZeneca | 19 | $449 |
| Boehringer Ingelheim | 7 | $243 |
| Chiesi USA, Inc. | 25 | $229 |
| Johnson & Johnson | 15 | $215 |
| Amgen | 14 | $177 |
| Livanova USA, Inc. | 1 | $143 |
| Amarin Pharma, Inc. | 7 | $104 |
| Bayer | 4 | $77 |
| Sanofi-aventis U.S. LLC | 5 | $76 |
| Pfizer | 4 | $64 |
| Abiomed | 2 | $61 |
| Cardiovascular Systems Inc. | 4 | $59 |
| Siemens Medical Solutions USA, Inc. | 2 | $55 |
| Stryker | 2 | $50 |
| Shockwave Medical, Inc | 2 | $40 |
| Terumo Medical Corporation | 2 | $38 |
| Merck | 2 | $37 |
| ZOLL Circulation Inc | 2 | $33 |
| Kestra Medical Technology Services, Inc. | 2 | $32 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Sanofi | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Portola Pharmaceuticals, LLC | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADVISA DR MRI SURESCAN$753
- Indigo System$720
- AZURE XT DR MRI SURESCAN$657
- Micra$548
- LifeSPARC System$143
- KENGREAL$134
- JARDIANCE$125
- CAMZYOS$125
How this compares
$9,786 in reported general payments places this provider in the 60th percentile of 46 interventional cardiology providers in West Virginia.
See all interventional cardiology providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 446 | $461,226 |
| EntrestoSacubitril/Valsartan | 195 | $247,915 |
| BrilintaTicagrelor | 191 | $163,220 |
| XareltoRivaroxaban | 113 | $124,599 |
| Repatha SureclickEvolocumab | 155 | $122,424 |
| CamzyosMavacamten | 11 | $82,165 |
| FarxigaDapagliflozin Propanediol | 63 | $58,280 |
| JardianceEmpagliflozin | 24 | $30,599 |
| Dofetilide | 128 | $23,793 |
| Repatha PushtronexEvolocumab | 23 | $16,935 |
| VascepaIcosapent Ethyl | 12 | $11,429 |
| Metoprolol Succinate | 574 | $7,193 |
| Prasugrel Hcl | 70 | $5,832 |
| Ezetimibe | 157 | $4,180 |
| Atorvastatin Calcium | 492 | $4,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $64 | $461,226446 claims |
| NovartisEntresto | $649 | $247,915195 claims |
| AstraZenecaBrilinta, Farxiga | $449 | $221,500254 claims |
| Johnson & JohnsonXarelto | $215 | $124,599113 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $535 | $82,16511 claims |
| Boehringer IngelheimJardiance | $243 | $30,59924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 46 interventional cardiology providers in West Virginia.
Other interventional cardiology in Parkersburg
- Christopher MillerParkersburg$3K
- Scott MandersParkersburg$48
- Mark BatesCharleston$288K
- Elie GharibSouth Charleston$240K
- Wissam GharibMorgantown$179K
- Anene UkaigweCharleston$168K
- Aravinda NanjundappaBeckley$166K
- Daniel SnavelyHuntington$120K
- Elise AndersonCharleston$38K
- Richard HanCharleston$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.